专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014176389A1 SOLID DOSAGE FORM CONTAINING ARABINOGALACTAN 审中-公开
标题翻译：含阿拉伯糖苷的固体剂型
公开(公告)号：WO2014176389A1
公开(公告)日：2014-10-30
申请号：PCT/US2014/035225
申请日：2014-04-24
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： THAKARE, Kalpana, N. , LEBO, David, B.
IPC分类号： A61K9/20
CPC分类号： A61K47/36 , A61K9/146 , A61K9/1652 , A61K9/5036 , A61K31/192 , A61K31/4178 , A61K31/427 , A61K31/4422 , A61K31/496
摘要： Provided is a dosage form for delivery of a therapeutic agent comprising a polymer matrix comprising arabinogalactan and a therapeutic agent uniformly dispersed in said polymer matrix. In some embodiments, the dosage form is selected from the group consisting of a microsphere, a nanosphere, a powder, a tablet, a film or a pellet enclosed in a capsule. Also provided are methods for preparing the dosage form.
摘要翻译：本发明提供用于递送治疗剂的剂型，其包含含有阿拉伯半乳聚糖的聚合物基质和均匀分散在所述聚合物基质中的治疗剂。在一些实施方案中，剂型选自包封在胶囊中的微球，纳米球，粉末，片剂，膜或丸粒。还提供了制备剂型的方法。

2. 发明申请

WO2014121093A1 FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION 审中-公开
标题翻译：融合蛋白质，使癌细胞破坏
公开(公告)号：WO2014121093A1
公开(公告)日：2014-08-07
申请号：PCT/US2014/014189
申请日：2014-01-31
申请人： THOMAS JEFFERSON UNIVERSITY
发明人： TYKOCINSKI, Mark, L.
IPC分类号： C12N15/62
CPC分类号： C07K16/2896 , A61K38/00 , C07K14/4703 , C07K14/525 , C07K14/70575 , C07K14/78 , C07K2319/00 , C07K2319/33 , C07K2319/74
摘要： Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.
摘要翻译：提供了包含阻断CD47与SIRPα的结合的多肽组分和结合并触发TRAIL受体或Fas的多肽的融合蛋白。还提供了一种治疗患者的癌症的方法，包括将本发明的融合蛋白施用于需要这种治疗的患者。

3. 发明申请

WO2014055289A1 IMMUNIZATION WITH RABIES VIRUS VECTOR EXPRESSING FOREIGN PROTEIN ANTIGEN 审中-公开
标题翻译：免疫外源蛋白抗原免疫病毒载体
公开(公告)号：WO2014055289A1
公开(公告)日：2014-04-10
申请号：PCT/US2013/061359
申请日：2013-09-24
申请人： THOMAS JEFFERSON UNIVERSITY
发明人： DIETZSCHOLD, Bernhard , HOOPER, Douglas, Craig , FABER, Milosz
IPC分类号： A61K39/205 , A61P31/14 , C12N7/04
CPC分类号： A61K39/155 , A61K39/0007 , A61K39/12 , A61K39/205 , A61K39/39 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N7/04 , C12N2760/18034 , C12N2760/18234 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , Y02A50/491
摘要： An immune response in a subject is elicited by a regiment comprising immunization with an attenuated recombinant rabies virus encoding at least one foreign protein antigen, and booster immunization with the at least one foreign protein antigen in a vehicle that does not contain adjuvant. The foreign protein antigen may comprise a prion protein antigen, a cancer-associated antigens, a viral antigen, a bacterial antigens, or a protozoal antigen. The prime/boost regimen produces predominantly IgG 2A/C and IgG 2B antibodies against the foreign protein antigen,, indicating a TH1 response. Rabies virus attenuation may be provided, for example, by one or more mutations in the rabies glycoprotein gene which confers attenuation of pathogenicity.
摘要翻译：受试者的免疫应答由包括用编码至少一种外来蛋白质抗原的减毒重组狂犬病病毒免疫的团体引发，以及在不含佐剂的载体中与所述至少一种外来蛋白质抗原进行加强免疫。外源蛋白抗原可以包含朊蛋白抗原，癌相关抗原，病毒抗原，细菌抗原或原生动物抗原。主要/升高方案主要产生抗外源蛋白抗原的IgG 2A / C和IgG 2B抗体，表明TH1反应。狂犬病病毒减弱可以例如通过狂犬病糖蛋白基因中一个或多个突变引起致病性的减弱而提供。

4. 发明申请

WO2013188529A1 USE OF ISOLATED BACTERIAL AMYLOIDS FOR TREATMENT OF INFLAMMATORY DISORDERS OR DISEASES OF THE EPITHELIUM 审中-公开
标题翻译：用于治疗炎性疾病或上皮疾病的隔离细菌脂质体的应用
公开(公告)号：WO2013188529A1
公开(公告)日：2013-12-19
申请号：PCT/US2013/045397
申请日：2013-06-12
申请人： TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： TUKEL, Cagla
IPC分类号： A61K39/00 , A61K39/38 , A61K45/00 , A61K47/00
CPC分类号： A61K38/164 , A61K38/1716 , A61K39/025 , A61K39/09
摘要： A method for treatment of a subject having an inflammatory disease of the epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to said subject. In embodiments, the composition is membrane-free. In embodiments, the composition comprises a curli fibril. In yet further embodiments, the isolated bacterial amyloid peptide is a CsgA polypeptide, a CsgA polypeptide fragment, a CsgB polypeptide or a CsgB polypeptide fragment. Also provided is a method for decreasing epithelium permeability in a tissue of a subject comprising epithelium comprising the step of administering an amount of a composition comprising an isolated bacterial amyloid peptide to the epithelium of the subject. In embodiments, the composition is membrane-free. In further embodiments, the composition comprises a curli fibril. In embodiments, the isolated bacterial amyloid peptide is a CsgA polypeptide, a CsgA polypeptide fragment, a CsgB polypeptide or a CsgB polypeptide fragment.
摘要翻译：用于治疗具有上皮炎性疾病的受试者的方法，包括向所述受试者施用一定量的包含分离的细菌淀粉样肽的组合物的步骤。在实施方案中，组合物是无膜的。在实施方案中，组合物包含curli原纤维。在另外的实施方案中，分离的细菌淀粉样肽是CsgA多肽，CsgA多肽片段，CsgB多肽或CsgB多肽片段。还提供了减少包含上皮的受试者组织中的上皮通透性的方法，其包括将一定量的包含分离的细菌淀粉样肽的组合物施用于受试者的上皮的步骤。在实施方案中，组合物是无膜的。在另外的实施方案中，组合物包含曲柳原纤维。在实施方案中，分离的细菌淀粉样肽是CsgA多肽，CsgA多肽片段，CsgB多肽或CsgB多肽片段。

5. 发明申请

WO2012166586A1 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译：取代的2-苄氧基-2H-苯并[b] [1,4]噻嗪-3（4H） - 酮及其衍生物及其治疗用途
公开(公告)号：WO2012166586A1
公开(公告)日：2012-12-06
申请号：PCT/US2012/039544
申请日：2012-05-25
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , MOUNT SINAI SCHOOL OF MEDICINE , REDDY, E., Premkumar , REDDY, M. V., Ramana
发明人： REDDY, E., Premkumar , REDDY, M. V., Ramana
IPC分类号： A61K31/5415 , C07D279/16 , A61K39/00
CPC分类号： C07D279/16 , A61K47/48384 , A61K47/6803 , C07D279/20 , C07D417/06 , C07D417/10
摘要： The present invention relates to compounds according to Formula I and salts thereof, wherein R 1 , R 2 , R 3, R 4 , Ar, and n are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating cellular proliferative disorders, such as cancer, with the compounds of Formula I.
摘要翻译：本发明涉及式I化合物及其盐，其中R 1，R 2，R 3，R 4，Ar和n如本文所定义。还提供了制备式I化合物的方法。本发明还包括用式I化合物治疗细胞增殖性疾病如癌症的方法。

6. 发明申请

WO2012155039A1 DIAGNOSIS AND TREATMENT OF COPD 审中-公开
标题翻译： COPD诊断与治疗
公开(公告)号：WO2012155039A1
公开(公告)日：2012-11-15
申请号：PCT/US2012/037501
申请日：2012-05-11
申请人： TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , MERALI, Salim , MONCADA, Camilo , KELSEN, Steven, G. , BARRERO, Carlos, A. , PEREZ LEAL, Oscar, Mauricio
发明人： MERALI, Salim , MONCADA, Camilo , KELSEN, Steven, G. , BARRERO, Carlos, A. , PEREZ LEAL, Oscar, Mauricio
IPC分类号： G01N33/68
CPC分类号： G01N33/6875 , G01N33/577 , G01N2440/12 , G01N2800/122 , G01N2800/56 , H01J49/0027
摘要： Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of diagnosis and/or staging are provided as well. Further provided is a method for treating COPD.
摘要翻译：提供了一种基于一种或多种组蛋白的检测来诊断和/或分期COPD的方法。在一些实施方案中，组蛋白是包含翻译后修饰的H3.3蛋白。在一些实施方案中，组蛋白是H2B，H3，H3.3或H4。还提供了用于实施诊断和/或分期方法的套件。还提供了治疗COPD的方法。

7. 发明申请

WO2012142142A3 ADIPONECTIN RECEPTOR AGONISTS AND METHODS OF USE 审中-公开
公开(公告)号：WO2012142142A3
公开(公告)日：2012-10-18
申请号：PCT/US2012/033099
申请日：2012-04-11
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM HIGHER EDUCATION , OTVOS, Laszlo , SURMACZ, Eva
发明人： OTVOS, Laszlo , SURMACZ, Eva
IPC分类号： C07K4/00 , A61K38/00
摘要： Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.

8. 发明申请

WO2012122228A3 BIOMARKERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
公开(公告)号：WO2012122228A3
公开(公告)日：2012-09-13
申请号：PCT/US2012/027998
申请日：2012-03-07
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , MERALI, Salim , KELSEN, Steven, G. , BARRERO, Carlos, A.
发明人： MERALI, Salim , KELSEN, Steven, G. , BARRERO, Carlos, A.
IPC分类号： G01N33/48 , G01N33/53
摘要： The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease ("COPD") but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.

9. 发明申请

WO2011146842A1 PROCESS FOR SYNTHESIS OF SILANE DIPEPTIDE ANALOGS 审中-公开
标题翻译：合成硅烷二肽类似物的方法
公开(公告)号：WO2011146842A1
公开(公告)日：2011-11-24
申请号：PCT/US2011/037352
申请日：2011-05-20
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , SIEBURTH, Scott McNeill , BO, Yingjian
发明人： SIEBURTH, Scott McNeill , BO, Yingjian
IPC分类号： C07F7/02
CPC分类号： C07F7/0827 , C07F7/0818
摘要： The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine.
摘要翻译：本发明提供了一种制备硅烷二肽类似物的方法，包括以下步骤：用锂金属处理取代的1,2-氧基甲硅烷的溶液，以形成取代的3-羟基丙基硅烷醇的二锂盐的溶液，取代的3-羟丙基硅烷醇的二锂盐与取代的烯胺。

10. 发明申请

WO2009002542A1 MULTI-DAY DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES 审中-公开
标题翻译：生物活性物质的多日交付
公开(公告)号：WO2009002542A1
公开(公告)日：2008-12-31
申请号：PCT/US2008/007983
申请日：2008-06-26
申请人： SAMOS PHARMACEUTICALS, LLC , KYDONIEUS, Agis
发明人： KYDONIEUS, Agis
IPC分类号： A61K39/00
CPC分类号： A61K47/481 , A61K9/0009 , A61K9/0019 , A61K9/0021 , A61K9/0043 , A61K47/48123 , A61K47/55 , A61K47/554
摘要： Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.
摘要翻译：公开了用于改变生物活性物质以实现这种物质的多日输送的组合物和方法，特别是通过口服或肠胃外给药。所述组合物包括缀合至具有合适的半衰期（通常超过一天）的载体的生物活性物质，其中缀合物任选地含有将载体与生物活性物质连接的间隔基。还公开了缀合物的药物制剂，以及将单剂量的生物活性物质的递送延长超过一天的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式